Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia. or B, with and without Inhibitors: An Integrated Analysis of Safety

被引：0

作者：

Acharya, Suchitra ^{[1
]}

Matino, Davide ^{[2
]}

Mahlangu, Johnny ^{[3
,4
]}

Turich, Carrie ^{[5
]}

Hwang, Eunhee ^{[6
]}

Hinnershitz, Tina ^{[7
]}

Mefyod, Eugeny ^{[8
]}

Palladino, Andrew ^{[6
]}

Biondo, Francesca ^{[7
]}

Gould, Travis ^{[5
]}

Teeter, John ^{[7
]}

机构：

[1] Cohen Childrens Med Ctr New York, New Hyde Pk, NY USA

[2] Thrombosis & Atherosclerosis Res Inst TaARI, Hamilton, ON, Canada

[3] Univ Witwatersrand, Johannesburg, South Africa

[4] Natl Hlth Lab Serv, Johannesburg, South Africa

[5] Pfizer Inc, New York, NY USA

[6] Pfizer Inc, Collegeville, PA USA

[7] Pfizer Inc, Groton, CT USA

[8] Pfizer Inc, Smolensk, Russia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174682

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 45 条

[41] Three- Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab
Shima, Midori
Takedani, Hideyuki
Kitsukawa, Kaoru
Taki, Masashi
Ishiguro, Akira
Nagae, Chiai
Nagao, Azusa
Nosaka, Daisuke
Kyogoku, Yui
Oki, Hiroki
Iwasaki, Keisuke
Nogami, Keiji
BLOOD, 2023, 142
[42] DNA-SEQUENCE ANALYSIS OF 3 INHIBITOR-POSITIVE HEMOPHILIA-B PATIENTS WITHOUT GROSS GENE DELETION - IDENTIFICATION OF 4 NOVEL MUTATIONS IN FACTOR-IX GENE
MATSUSHITA, T
TANIMOTO, M
YAMAMOTO, K
SUGIURA, I
HAMAGUCHI, M
TAKAMATSU, J
KAMIYA, T
SAITO, H
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1990, 116 (04): : 492 - 497
[43] Safety of antihemophilic factor recombinant plasma/albumin-free method [rAHF-PFM] in hemophilia A patients with low titer inhibitors or a personal history of inhibitor: A meta-analysis of ADVATE Post-Authorization Safety Studies data
Marcucci, Maura
Cheng, Ji
Romanov, Vadim
Thabane, Lehana
Iorio, Alfonso
HAEMOPHILIA, 2014, 20 : 46 - 46
[44] A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (imc3g3), a human anti-platelet-derived growth factor a (pdgfra) monoclonal antibody, in advanced soft tissue sarcoma (sts)
Tap, W.
Jones, R. L.
Chmelowski, B.
Elias, A. A.
Adkins, D.
Van Tine, B. A.
Agulnik, M.
Cooney, M.
Livingston, M. B.
Pennock, G.
Quin, A.
Shahir, A.
Ilaria, R., Jr.
Conti, I.
Schwartz, G. K.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 174 - 174
[45] A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (pdgfrα) monoclonal antibody, in advanced soft tissue sarcoma (sts)
Tap, W.
Jones, R. L.
Chmielowski, B.
Elias, A. D.
Adkins, D.
Van Tine, B. A.
Agulnik, M.
Cooney, M.
Livingston, M. B.
Pennock, G.
Qin, A.
Shahir, A.
Ilaria, R., Jr.
Conti, I.
Schwartz, G.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →